The global surgical robotics landscape is undergoing a structural metamorphosis, transitioning from a category defined by venture-backed pioneerism to one increasingly governed by the industrial logic of private equity and large-cap consolidation. While the initial era of robotic-assisted surgery (RAS) was dominated by the "Intuitive Playbook", a high-margin, capital-intensive model focused on soft-tissue dominance, the 2026 horizon indicates a significant diversification of